Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism
- 1 January 2022
- book chapter
- Published by Elsevier BV
- Vol. 165, 63-89
- https://doi.org/10.1016/bs.irn.2022.04.004
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Chronic Interferon-α Decreases Dopamine 2 Receptor Binding and Striatal Dopamine Release in Association with Anhedonia-Like Behavior in Nonhuman PrimatesNeuropsychopharmacology, 2013
- The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's diseaseFrontiers in Computational Neuroscience, 2013
- Salivary cortisol levels in Parkinson's disease and its correlation to risk behaviourJournal of Neurology, Neurosurgery & Psychiatry, 2011
- Viral parkinsonismBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Multiple hit hypotheses for dopamine neuron loss in Parkinson's diseaseTrends in Neurosciences, 2007
- Blood–brain barrier transport of pramipexole, a dopamine D2 agonistLife Sciences, 2007
- Acute Levodopa Intake and Associated Cortisol Decrease in Patients With Parkinson DiseaseClinical Neuropharmacology, 2007
- Transforming growth factor-α directly augments histidine decarboxylase and vesicular monoamine transporter 2 production in rat enterochromaffin-like cellsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- Chronic Cold Stress Reduces the Spontaneous Activity of Ventral Tegmental Dopamine NeuronsNeuropsychopharmacology, 2001
- A Manual of Diseases of the Nervous SystemThe American Journal of Psychology, 1888